Azilsartan in Chinese Patients With Mild and Moderate Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.

Also called NCT02609490

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 304 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02609490
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02609490. Randomized; triple masking; primary purpose treatment. Start 2015-09 (actual); primary completion 2017-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Azilsartan in Chinese Patients With Mild and Moderate Hypertension
Condition
Hypertension
Intervention (Drug)
Azilsartan tablets
Intervention (Drug)
Azilsartan placebo tablets
Intervention (Drug)
Olmesartan medoxomil tablets
Intervention (Drug)
olmesartan medoxomil placebo tablets
Lead sponsor
Lee's Pharmaceutical Limited (class: industry)

Record details

Record id
cardio:ct-nct02609490
Content hash
dde671879650494ac230c4aa6933f0b3ae73e45ade19117d612fb5b7104bca23